

# Wholesale Acquisition Cost (WAC) Disclosure for Colorado Prescribers

This information is provided pursuant to Colorado law, which requires prescription drug manufacturers to disclose the Wholesale Acquisition Cost (WAC) of marketed drugs when engaging in prescription drug marketing activities with Colorado prescribers. WAC represents the manufacturer’s published list price to wholesalers and does not reflect the actual cost paid by patients. The WAC of Lumvoa™ (veligrotug-vvze) as of June 26, 2026 is provided below.

| Product/NDC <sup>1</sup>    | WAC per vial <sup>2*</sup> | Total treatment cost (based on an 82-kg patient) <sup>1-4†</sup> |
|-----------------------------|----------------------------|------------------------------------------------------------------|
| Lumvoa<br>NDC: 85166-001-01 | \$44,800                   | \$448,000                                                        |

Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class,” which is defined as “similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.”

There are no generic prescription drugs available in the same therapeutic class as Lumvoa.

<sup>\*</sup>The WAC is the manufacturer’s undiscounted list price for a pharmaceutical product when it is sold to wholesalers, distributors, or other direct purchasers. The WAC does not represent an actual transaction price and does not include discounts, rebates, or other reductions in price.

<sup>†</sup>Based on 10 mg/kg dosage every 3 weeks for 5 infusions, with vial counts rounded up to the nearest whole vial. Assumes a patient weight of 82 kg, which is consistent with the average patient weight observed in the THRIVE trial and aligns with the CDC-reported average adult weight.<sup>1,3,4</sup>

CDC, Centers for Disease Control and Prevention; NDC, National Drug Code.

**References:** **1.** Lumvoa™ (veligrotug-vvze) prescribing information. Viridian Therapeutics, Inc. 2026. **2.** Data on file. Viridian Therapeutics, Inc. June 26, 2026. **3.** Anthropomorphic Reference Data for Children and Adults: United States, August 2021-2023. National Center for Health Statistics (US). June 25, 2025. Accessed June 1, 2026. <https://stacks.cdc.gov/view/cdc/174595> **4.** Data on file. Viridian Therapeutics, Inc. August 22, 2025.

